Interim Analysis Started for A021501

New treatment options are available for patients with borderline resectable pancreatic cancer.  Exciting research is underway by the Alliance to help to improve the care of patients with previously unresectable pancreatic cancer.

Scheme for Alliance Trial

The Alliance recent completed a clinical trial investigating preoperative chemotherapy and radiation for borderline resectable pancreatic cancer.  This trial has promising results Alliance trial A021101.

Follow-up study A021501 is now undergoing interim analysis.

What is A021501?

Combination Chemotherapy With or Without Hypofractionated Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer

This randomized controlled trial investigates the benefit of preoperative chemotherapy and radiation in patients with borderline resectable pancreatic cancer.

While the majority of patients diagnosed in the United States will not have the opportunity for surgery due to metastatic disease, opportunities for surgery are growing.  A021501 will help us better understand the treatment of patients with borderline resectable disease.

For more information regarding this trial, contact us!

Change in Trial Status: Interim Analysis Started for Alliance Borderline Resectable Pancreatic Cancer Trial